AFT Pharmaceuticals (AFT): 1H23 Result – Initial Impressions
AFT Pharmaceuticals (AFT) reported a below expectations 1H23 result with EBIT ex licensing income (underlying EBIT) of NZ$3.4m versus our NZ$5.0m...
268 Views
AFT Pharmaceuticals: A Picture of Health; OUTPERFORM
We initiate full coverage of AFT Pharmaceuticals (AFT) with a 12 month target price of NZ$5.00 and an OUTPERFORM rating; we think the market under...
132 Views
AFT Pharmaceuticals: 1H22 Result — A Bump in the Road
AFT Pharmaceuticals1H22 Result — A Bump in the Road RESEARCH INSIGHTS AFT Pharmaceuticals (AFT) reported a lower than expected underlying 1H22...
795 Views
AFT Pharmaceuticals (AFT): 1H22 Result – Initial Impressions
AFT Pharmaceuticals (AFT)1H22 Result – Initial Impressions AFT Pharmaceuticals (AFT) reported a 1H22 result below expectations, but significantly...
762 Views
Company Coverage: Temporary Analyst Change
Company Coverage Temporary Analyst Change We temporarily transfer coverage of the following companies to Matt Montgomerie due to...
277 Views